With the Dow down 9% and the Nasdaq having plunged 15% since New Year’s, it has been a lousy start to the year on Wall Street—but you wouldn’t know it from the bang-up performance of Intrexon, Cerus and Inovio Pharmaceuticals. What do these three biotech companies have in common? They’re all hoping to cash in on the rise of Zika virus, the mosquito-borne illness that originated in Brazil and has been linked to birth defects. All three companies are working on methods for preventing or treating the virus.

from Forbes – Tech http://ift.tt/1RlUvHK
via IFTTT